Skip to main content
. 2020 May 19;42(1):48–57. doi: 10.1093/carcin/bgaa048

Figure 4.

Figure 4.

Effect of CRISPR/Cas9-mediated RLIP knockdown on the size of subcutaneously implanted human BC (MDA-MB231) xenograft tumors in nude mice. Thirty 10-week-old mice were divided into five groups: (1) MDA-MB231, (2) MDA-MB231-Cas9/sg control, (3) MDA-MB231-Cas9/sg control + doxycycline, (4) MDA-MB231-Cas9/sg RLIP, and (5) MDA-MB231-Cas9/sg RLIP + doxycycline. Tumors grew more slowly in mice that received MDA-MB231-Cas9/sg RLIP + doxycycline (Group #5) than in mice in the other groups (panel A). The average wet weights of the tumors at day 60 was also lower for the Cas9/sg RLIP + doxycycline group (0.45 g) than for the other groups (Group #1: 2.1 g, Group #2: 2.0 g, Group #3: 1.8 g, and Group #4: 1.5 g, respectively; panel B). The Cas9/sg RLIP + doxycycline-treated mice did not exhibit any signs of overt toxicity, such as impaired movement or posture, indigestion, or areas of redness or swelling. The initial and final body weights of the controls and treated mice did not differ significantly (panel C).